nach oben

Erschienen in:

30.06.2016 | Original articles

Identifying disrupted pathways by tracking altered modules in type 2 DM-related heart failure

verfasst von: H. Liu, X. Han, Y. Li

Erschienen in: Herz | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to screen disrupted pathways in type 2 diabetes mellitus (T2DM) heart failure by systematically tracking the altered modules of reweighted protein–protein interaction (PPI) networks.

Methods

We implemented systematic identification and comparison of modules across non-T2DM and T2DM heart failure subjects by integrating gene expression data and PPI networks. The PPI networks of non-T2DM heart failure and T2DM heart failure were constructed and reweighted by means of Spearman’s correlation coefficient (SCC). Subsequently, a clique-merging algorithm was used to explore the modules in the PPI network, followed by the identification of disrupted modules based on a maximum-weight bipartite matching and sorting in descending order. Finally, pathway enrichment analyses were conducted for genes in disrupted modules to determine the biological pathways in T2DM heart failure.

Results

By comparing the modules of non-T2DM heart failure and T2DM heart failure, 804 disrupted modules were explored. The genes in disrupted modules were significantly enriched in 39 categories (p < 1.00E-06). Of these, the most significant pathways were the focal adhesion, vascular endothelial growth factor (VEGF) signaling, and mitogen-activated protein kinase (MAPK) signaling pathways.

Conclusion

The identified disrupted pathways – focal adhesion, VEGF signaling, and MAPK signaling – might play important roles in the progression of T2DM heart failure.

Mcmurray JJ, Pfeffer MA (2005) Heart failure. Lancet 365(9474):1877–1889CrossRefPubMed

Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223CrossRefPubMed

Struthers AD, Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: A new way of reducing cardiac deaths. Lancet 359(9315):1430–1432CrossRefPubMed

Stone PH et al (1989) The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 14(1):49–57CrossRefPubMed

Estep JD, Aguilar D (2006) Diabetes and heart failure in the post-myocardial infarction patient. Curr Heart Fail Rep 3(4):164–169CrossRefPubMed

Hotamisligil GS, Shargill NS (1993) Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259(5091):87–91CrossRefPubMed

Volz HC et al (2010) HMGB1: The missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105(6):805–820CrossRefPubMed

Heather LC, Clarke K (2011) Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50(4):598–605CrossRefPubMed

Shen E et al (2009) Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58(10):2386–2395CrossRefPubMedPubMedCentral

10.

Gavin AC et al (2006) Proteome survey reveals modularity of the yeast cell machinery. Nature 440(7084):631–636CrossRefPubMed

11.

Zhao J et al (2012) Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics 28(22):2940–2947CrossRefPubMed

12.

Jordán F, Nguyen TP, Liu WC (2012) Studying protein-protein interaction networks: a systems view on diseases. Brief Funct Genomics 11(6):497–504CrossRefPubMed

13.

Chao W et al (2012) Integrating gene expression and protein-protein interaction network to prioritize cancer-associated genes. BMC Bioinformatics 13(14):182

14.

Liu G, Wong L, Chua HN (2009) Complex discovery from weighted PPI networks. Bioinformatics 25(15):1891–1897CrossRefPubMed

15.

Srihari S, Ragan MA (2013) Systematic tracking of dysregulated modules identifies novel genes in cancer. Bioinformatics 29(12):1553–1561CrossRefPubMed

16.

Greco S et al (2012) MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61(6):1633–1641CrossRefPubMedPubMedCentral

17.

Irizarry RA et al (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:4CrossRef

18.

Bolstad BM et al (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2):185–193CrossRefPubMed

19.

Szklarczyk D et al (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39(suppl 1):D561–D568CrossRefPubMed

20.

Hauke J, Kossowski T (2011) Comparison of values of Pearson’s and Spearman’s correlation coefficients on the same sets of data. Quaestiones Geogr 30(2):87–93

21.

Srihari S, Leong HW (2013) A survey of computational methods for protein complex prediction from protein interaction networks. J Bioinform Comput Biol 11(02):1230002CrossRefPubMed

22.

Tomita E, Tanaka A, Takahashi H (2006) The worst-case time complexity for generating all maximal cliques and computational experiments. Theor Comput Sci 363(1):28–42CrossRef

23.

Gabow HN (1976) An efficient implementation of Edmonds’ algorithm for maximum matching on graphs. J Acm 23(2):221–234 (JACM)CrossRef

24.

Huang DW, Sherman BT, Lempicki RA (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57CrossRef

25.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 72(4):289–300 (Series B (Methodological))

26.

Shah AD et al (2015) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol 3(14):105–113CrossRefPubMedPubMedCentral

27.

Chen CS et al (2003) Cell shape provides global control of focal adhesion assembly. Biochem Biophys Res Commun 307(2):355–361CrossRefPubMed

28.

Taylor JM, Rovin JD, Parsons JT (2000) A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J Biol Chem 275(25):19250–19257CrossRefPubMed

29.

Chien KR (1999) Stress pathways and heart failure. Cell 98(5):555–558CrossRefPubMed

30.

Bayer AL et al (2002) PYK2 expression and phosphorylation increases in pressure overload-induced left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 283(2):H695–H706CrossRefPubMed

31.

Lopes MM et al (2007) Increased expression and phosphorylation of focal adhesion kinase correlates with dysfunction in the volume-overloaded human heart. Clin Sci 113(3–4):195–204CrossRefPubMed

32.

Eble DM et al (2000) Endothelin-induced cardiac myocyte hypertrophy: Role for focal adhesion kinase. Ajp Heart Circ Physiol 278(5):H1695–H707

33.

Shen E et al (2011) MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol 179(2):639–650CrossRefPubMedPubMedCentral

34.

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611CrossRefPubMed

35.

Landray MJ et al (2004) Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis p:244–253CrossRef

36.

Lip GY, Chung I (2005) Vascular endothelial growth factor and angiogenesis in heart failure. J Card Fail 11(4):285–287CrossRefPubMed

37.

Mutunga M et al (2001) Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 163:195–200CrossRefPubMed

38.

Shimojo N et al (2007) Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 293(1):H474–H481CrossRefPubMed

39.

Sun J et al (2010) Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: The role of mitochondrial reactive oxygen species. Mol Cell Biochem 343(1–2):27–35CrossRefPubMed

40.

Muslin A (2008) MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci 115:203–218CrossRefPubMedPubMedCentral

41.

Cheng YC et al (2009) Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 325(1–2):15–23CrossRefPubMed

42.

Chang SH et al (2011) Garlic Oil Alleviates MAPKs- and IL-6-mediated Diabetes-related Cardiac Hypertrophy in STZ–induced DM Rats. Evidence-based Complementary Altern Med 2011(1):1–11

43.

Kuo WW et al (2011) Attenuated cardiac Mitochondrial-dependent Apoptotic effects by Li-Fu formula in hamsters fed with a Hypercholesterol diet. Evid Based Complement Alternat Med 2011(5):530345PubMedPubMedCentral

Titel: Identifying disrupted pathways by tracking altered modules in type 2 DM-related heart failure
verfasst von: H. Liu
X. Han
Y. Li
Publikationsdatum: 30.06.2016
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 1/2017
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-016-4445-1

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Neu bewertet: Klinische Bedeutung des HDL-Cholesterins

Results of pericardiectomy for constrictive pericarditis

Kardiogener Schock: wann Vasopressoren, wann Inotropika?

Computertomographie bei Patienten mit stabiler Angina Pectoris

ECMO in cardiac arrest and cardiogenic shock